Literature DB >> 24326404

Selective detection of complementarity-determining regions of monoclonal antibody by limiting protease access to the substrate: nano-surface and molecular-orientation limited proteolysis.

Noriko Iwamoto1, Takashi Shimada, Yukari Umino, Chikage Aoki, Yutaka Aoki, Taka-Aki Sato, Akinobu Hamada, Hitoshi Nakagama.   

Abstract

We report a novel method for the selective proteolysis by limiting protease access to the substrate, which we have named nano-surface and molecular-orientation limited (nSMOL) proteolysis. We focus on the identification of the Fab and quantitation of antibodies. This method successfully performed limited proteolysis on the Fab.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24326404     DOI: 10.1039/c3an02104a

Source DB:  PubMed          Journal:  Analyst        ISSN: 0003-2654            Impact factor:   4.616


  11 in total

1.  Human endotrophin as a driver of malignant tumor growth.

Authors:  Dawei Bu; Clair Crewe; Christine M Kusminski; Ruth Gordillo; Alexandra L Ghaben; Min Kim; Jiyoung Park; Hui Deng; Wei Xiong; Xiao-Zheng Liu; Per Eystein Lønning; Nils Halberg; Adan Rios; Yujun Chang; Anneliese Gonzalez; Ningyan Zhang; Zhiqiang An; Philipp E Scherer
Journal:  JCI Insight       Date:  2019-03-21

2.  Restricted Proteolysis and LC-MS/MS To Evaluate the Orientation of Surface-Immobilized Antibodies.

Authors:  Min Shen; Di Jiang; P I Thilini De Silva; Boya Song; James F Rusling
Journal:  Anal Chem       Date:  2019-03-14       Impact factor: 6.986

3.  Comparison of Bevacizumab Quantification Results in Plasma of Non-small Cell Lung Cancer Patients Using Bioanalytical Techniques Between LC-MS/MS, ELISA, and Microfluidic-based Immunoassay.

Authors:  Noriko Iwamoto; Megumi Takanashi; Takashi Shimada; Jiichiro Sasaki; Akinobu Hamada
Journal:  AAPS J       Date:  2019-08-20       Impact factor: 4.009

4.  N-terminus of Etanercept is Proteolytically Processed by Dipeptidyl Peptidase-4.

Authors:  Sho Masui; Atsushi Yonezawa; Kotoko Yokoyama; Noriko Iwamoto; Takashi Shimada; Akira Onishi; Hideo Onizawa; Takayuki Fujii; Kosaku Murakami; Koichi Murata; Masao Tanaka; Shunsaku Nakagawa; Daiki Hira; Kotaro Itohara; Satoshi Imai; Takayuki Nakagawa; Makoto Hayakari; Shuichi Matsuda; Akio Morinobu; Tomohiro Terada; Kazuo Matsubara
Journal:  Pharm Res       Date:  2022-08-19       Impact factor: 4.580

5.  Application of nSMOL coupled with LC-MS bioanalysis for monitoring the Fc-fusion biopharmaceuticals Etanercept and Abatacept in human serum.

Authors:  Noriko Iwamoto; Kotoko Yokoyama; Megumi Takanashi; Atsushi Yonezawa; Kazuo Matsubara; Takashi Shimada
Journal:  Pharmacol Res Perspect       Date:  2018-07-24

6.  Plasma infliximab monitoring contributes to optimize Takayasu arteritis treatment: a case report.

Authors:  Sho Masui; Atsushi Yonezawa; Kazushi Izawa; Makoto Hayakari; Kayoko Asakura; Risa Taniguchi; Masahiko Isa; Hirofumi Shibata; Takahiro Yasumi; Ryuta Nishikomori; Junko Takita; Kazuo Matsubara
Journal:  J Pharm Health Care Sci       Date:  2019-05-02

7.  Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.

Authors:  Brendan D Curti; Yoshinobu Koguchi; Rom S Leidner; Annah S Rolig; Elizabeth R Sturgill; Zhaoyu Sun; Yaping Wu; Venkatesh Rajamanickam; Brady Bernard; Ian Hilgart-Martiszus; Christopher B Fountain; George Morris; Noriko Iwamoto; Takashi Shimada; ShuChing Chang; Peter G Traber; Eliezer Zomer; J Rex Horton; Harold Shlevin; William L Redmond
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

8.  Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab.

Authors:  Yoshinobu Koguchi; Noriko Iwamoto; Takashi Shimada; Shu-Ching Chang; John Cha; Brendan D Curti; Walter J Urba; Brian D Piening; William L Redmond
Journal:  J Immunother Cancer       Date:  2021-10       Impact factor: 13.751

9.  Understanding How Staphylococcal Autolysin Domains Interact With Polystyrene Surfaces.

Authors:  Radha P Somarathne; Emily R Chappell; Y Randika Perera; Rahul Yadav; Joo Youn Park; Nicholas C Fitzkee
Journal:  Front Microbiol       Date:  2021-05-19       Impact factor: 5.640

10.  Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum.

Authors:  Noriko Iwamoto; Kotoko Yokoyama; Megumi Takanashi; Atsushi Yonezawa; Kazuo Matsubara; Takashi Shimada
Journal:  Curr Pharm Biotechnol       Date:  2018       Impact factor: 2.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.